Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harmony Biosciences Holdings Inc (HRMY)

Harmony Biosciences Holdings Inc (HRMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,671,605
  • Shares Outstanding, K 57,841
  • Annual Sales, $ 868,450 K
  • Annual Income, $ 158,690 K
  • EBIT $ 208 M
  • EBITDA $ 233 M
  • 60-Month Beta 0.88
  • Price/Sales 1.90
  • Price/Cash Flow 8.98
  • Price/Book 1.90

Options Overview Details

View History
  • Implied Volatility 72.17% (-0.81%)
  • Historical Volatility 61.66%
  • IV Percentile 77%
  • IV Rank 40.56%
  • IV High 127.87% on 09/15/25
  • IV Low 34.16% on 12/17/25
  • Expected Move (DTE 17) 3.40 (11.76%)
  • Put/Call Vol Ratio 1.91
  • Today's Volume 67
  • Volume Avg (30-Day) 656
  • Put/Call OI Ratio 2.14
  • Today's Open Interest 13,856
  • Open Int (30-Day) 8,368
  • Expected Range 25.50 to 32.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 0.76
  • Number of Estimates 3
  • High Estimate 0.82
  • Low Estimate 0.71
  • Prior Year 0.78
  • Growth Rate Est. (year over year) -2.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.90 +11.57%
on 02/24/26
38.37 -24.68%
on 02/03/26
-8.94 (-23.63%)
since 02/02/26
3-Month
25.90 +11.57%
on 02/24/26
40.87 -29.29%
on 12/15/25
-7.11 (-19.74%)
since 12/02/25
52-Week
25.52 +13.24%
on 10/20/25
40.87 -29.29%
on 12/15/25
-4.95 (-14.62%)
since 02/28/25

Most Recent Stories

More News
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements...

HRMY : 28.90 (+1.26%)
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX ® (pitolisant) tablets...

HRMY : 28.90 (+1.26%)
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, before the open of the U.S. financial...

HRMY : 28.90 (+1.26%)
Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Jeffrey M. Dayno, M.D., President and Chief Executive...

HRMY : 28.90 (+1.26%)
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

Data presented at the 2025 American Epilepsy Society Annual Meeting

HRMY : 28.90 (+1.26%)
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will highlight new open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing...

HRMY : 28.90 (+1.26%)
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

New Drug Application to be submitted in early 2026; target PDUFA in Q1 2027 Utility patent applications filed with potential exclusivity to 2044

HRMY : 28.90 (+1.26%)
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

BP1.15205 is a differentiated chemical scaffold, demonstrating high potency and selectivity in preclinical studies with a favorable safety profile and the potential for once-daily dosing ...

HRMY : 28.90 (+1.26%)
Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Citi's 2025 Global Healthcare...

HRMY : 28.90 (+1.26%)
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

WAKIX® (pitolisant) Franchise Delivers Net Revenue of $239M in Q3 2025 (+29% YoY Growth) Record Increase in Average Number of Patients of Approximately 500 to Achieve...

HRMY : 28.90 (+1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 31.05
2nd Resistance Point 30.13
1st Resistance Point 29.51
Last Price 28.90
1st Support Level 27.97
2nd Support Level 27.05
3rd Support Level 26.43

See More

52-Week High 40.87
Fibonacci 61.8% 35.01
Fibonacci 50% 33.19
Fibonacci 38.2% 31.38
Last Price 28.90
52-Week Low 25.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar